• Our Professionals
  • Our Work
  • Our Insights
  • Firm
  • Careers
  • Tools
Finnegan
    • AIA Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • IP FDA Blog
    • Prosecution First Blog
  • Articles
  • IP Updates
  • Podcasts
  • Events
  • Webinars
  • Books

IP FDA Blog

FDA Guidance on Safety Testing of Drug Metabolites

March 18, 2020

By Brandon T. Andersen

Edited by M. David Weingarten, Ph.D.

On March 5, 2020, FDA issued final guidance on Safety Testing of Drug Metabolites. The guidance provides recommendations to industry on when and how to identify and characterize drug metabolites should nonclinical toxicity need to be evaluated. The guidance supersedes FDA guidance published in 2016 and aligns FDA guidance with the ICH guidance for industry M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals.

Nonclinical evaluation of drug safety usually includes standard animal toxicology studies in which drug exposure is assessed. Drug plasma concentration and systemic exposure in the nonclinical studies are compared with systemic exposure in humans to assess potential risks and guide monitoring in clinical studies. In some cases, however, a drug’s metabolic profile in humans is significantly different than in the animals used during standard testing. For example, the metabolite may only be formed in humans or be present at higher levels in humans than in the animal species used in the toxicology testing with the parent drug. FDA calls such a metabolite a disproportionate drug metabolite. Standard nonclinical testing does little to evaluate the toxicity of these metabolites to humans. Therefore, these metabolites, especially those that present at greater than 10 percent of total drug-related exposure at the steady state, should be considered for safety assessment.

The guidance states that there are two general approaches sponsors can consider to assess the effect of the drug metabolite. The first approach is to identify an animal species that routinely forms the metabolite at levels equivalent to or greater than the human exposure and investigate the drug’s toxicity in that species. The second approach, if the first approach is not possible, is to synthesize the metabolite and directly administer it to the animal for further safety evaluation. FDA acknowledges the difficulties of synthesizing a specific metabolite and the complexities that accompany direct administration but reaffirms the importance of identifying and evaluating the potential toxicity of the drug metabolite to ensure clinical safety.  

Sponsors should identify the metabolic profile of the drug at different stages of the drug development process using in vitro and in vivo methods. In vitro studies, which should generally be conducted before initiating clinical trials, can use liver microsomes, liver slices, or hepatocytes from animals and humans. Those results will either be confirmed or reveal quantitative and/or qualitative differences in metabolism across species by in vivo metabolism studies in nonclinical test species. The latter situation may pose safety concerns, so FDA recommends sponsors conduct in vivo metabolic evaluation in humans “as early as feasible.”

The guidance also discusses general considerations, such as drug indication and patient population, when designing a nonclinical study for a disproportionate drug metabolite and recommended studies, including genotoxicity, embryo-fetal development toxicity, and carcinogenicity studies, for assessing the safety of metabolites. Such safety assessments, if warranted, should be completed and study reports should be provided to FDA before beginning large-scale clinical trials. 

Readers are encouraged to read the final guidance, also available on FDA’s website.

Tags

FDA Guidance

Related Industries

Life Sciences

Pharmaceutical

Contacts

Brandon_Andersen
Brandon T. Andersen
Associate
Washington, D.C.
+1 202 408 4032
Email
David_Weingarten
M. David Weingarten, Ph.D.
Partner
Atlanta, GA
+1 404 653 6457
Email

Copyright © 2020 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Webinar

Patenting Pharmaceutical Drug Formulations: Withstanding Litigation and PTAB Challenges

February 16, 2021

Webinar

Webinar

Comparison of EPO Oppositions and USPTO PTAB Proceedings

January 28, 2021

Webinar

Webinar

Sanofi, Vanda, and GSK, a New Year Voyage through the Land of Induced Infringement

January 21, 2021

Webinar

Federal Circuit IP Blog

Disavowal of Infringement Case Eliminates Article III Standing for Appeal of IPR

January 13, 2021

Federal Circuit IP Blog

Spotlight on Upcoming Oral Arguments – January 2021

January 4, 2021

IP FDA Blog

Update to the Purple Book in Recent COVID-19 Stimulus Bill and Implications for BPCIA Litigation

December 23, 2020

INCONTESTABLE® Blog

The Copyright Office Will Not Weigh in on Philadelphia Phillies’ Copyright Dispute

December 22, 2020

AIA Blog

New PTAB Final Rule Places Burden on Patent Owner to Show Motion to Amend Complies with Statutory and Regulatory Requirements

December 21, 2020

Webinar

Inducement in a Pharmaceutical, Post-Launch Non-Hatch-Waxman World

December 17, 2020

Webinar

Due to international data regulations, we’ve recently updated our privacy policy. Click here to read our privacy policy in full.

We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.

  • Privacy
  • Disclaimer
  • EEO Statement

© 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP